Multivariate prognostic factor analyses for allografted patients
| Endpoint and variable . | Multivariate analysis . | |||
|---|---|---|---|---|
| P value . | HR . | LowerCL . | UpperCL . | |
| Overall survival | ||||
| TCD vs no TCD | .004 | 3.46 | 1.49 | 8.04 |
| Refractory at HSCT vs sensitive | .042 | 2.40 | 1.03 | 5.56 |
| Fludara refractory vs sensitive | .13 | 2.61 | 0.75 | 9.16 |
| Age (per year) | .36 | 0.98 | 0.93 | 1.03 |
| TP53 mutated vs unmutated | .91 | 1.05 | 0.44 | 2.50 |
| SF3B1 mutated vs unmutated | .60 | 0.79 | 0.33 | 1.88 |
| NOTCH1 mutated vs unmutated | .53 | 0.69 | 0.22 | 2.16 |
| Event-free survival | ||||
| TCD vs no TCD | .004 | 2.79 | 1.39 | 5.60 |
| Refractory at HSCT vs sensitive | .002 | 3.13 | 1.53 | 6.38 |
| Fludara refractory vs sensitive | .93 | 1.04 | 0.46 | 2.32 |
| Age (per year) | .22 | 0.98 | 0.94 | 1.02 |
| TP53 mutated vs unmutated | .25 | 0.66 | 0.32 | 1.34 |
| SF3B1 mutated vs unmutated | .21 | 0.63 | 0.32 | 1.29 |
| NOTCH1 mutated vs unmutated | .42 | 0.68 | 0.27 | 1.74 |
| Endpoint and variable . | Multivariate analysis . | |||
|---|---|---|---|---|
| P value . | HR . | LowerCL . | UpperCL . | |
| Overall survival | ||||
| TCD vs no TCD | .004 | 3.46 | 1.49 | 8.04 |
| Refractory at HSCT vs sensitive | .042 | 2.40 | 1.03 | 5.56 |
| Fludara refractory vs sensitive | .13 | 2.61 | 0.75 | 9.16 |
| Age (per year) | .36 | 0.98 | 0.93 | 1.03 |
| TP53 mutated vs unmutated | .91 | 1.05 | 0.44 | 2.50 |
| SF3B1 mutated vs unmutated | .60 | 0.79 | 0.33 | 1.88 |
| NOTCH1 mutated vs unmutated | .53 | 0.69 | 0.22 | 2.16 |
| Event-free survival | ||||
| TCD vs no TCD | .004 | 2.79 | 1.39 | 5.60 |
| Refractory at HSCT vs sensitive | .002 | 3.13 | 1.53 | 6.38 |
| Fludara refractory vs sensitive | .93 | 1.04 | 0.46 | 2.32 |
| Age (per year) | .22 | 0.98 | 0.94 | 1.02 |
| TP53 mutated vs unmutated | .25 | 0.66 | 0.32 | 1.34 |
| SF3B1 mutated vs unmutated | .21 | 0.63 | 0.32 | 1.29 |
| NOTCH1 mutated vs unmutated | .42 | 0.68 | 0.27 | 1.74 |
Missing values (TCD 0; Refractory/ sensitive at HSCT 1; Fludara refractory/sensitive 31; age 0; TP53/17p abn 17; SF3B1 mut 19; NOTCH1 mut 19) were considered as individual category for each covariate. Results of missing value categories are not included in the table.
CL, confidence limit; TCD, in vivo T-cell depletion with alemtuzumab.